207 related articles for article (PubMed ID: 15930356)
1. Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer.
Altorki NK; Port JL; Zhang F; Golijanin D; Thaler HT; Duffield-Lillico AJ; Subbaramaiah K; Dannenberg AJ
Clin Cancer Res; 2005 Jun; 11(11):4191-7. PubMed ID: 15930356
[TBL] [Abstract][Full Text] [Related]
2. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.
Csiki I; Morrow JD; Sandler A; Shyr Y; Oates J; Williams MK; Dang T; Carbone DP; Johnson DH
Clin Cancer Res; 2005 Sep; 11(18):6634-40. PubMed ID: 16166442
[TBL] [Abstract][Full Text] [Related]
3. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer.
Altorki NK; Keresztes RS; Port JL; Libby DM; Korst RJ; Flieder DB; Ferrara CA; Yankelevitz DF; Subbaramaiah K; Pasmantier MW; Dannenberg AJ
J Clin Oncol; 2003 Jul; 21(14):2645-50. PubMed ID: 12860939
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
Mutter R; Lu B; Carbone DP; Csiki I; Moretti L; Johnson DH; Morrow JD; Sandler AB; Shyr Y; Ye F; Choy H
Clin Cancer Res; 2009 Mar; 15(6):2158-65. PubMed ID: 19276291
[TBL] [Abstract][Full Text] [Related]
6. COX-2 inhibition and lung cancer.
Sandler AB; Dubinett SM
Semin Oncol; 2004 Apr; 31(2 Suppl 7):45-52. PubMed ID: 15179623
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Reckamp KL; Krysan K; Morrow JD; Milne GL; Newman RA; Tucker C; Elashoff RM; Dubinett SM; Figlin RA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3381-8. PubMed ID: 16740761
[TBL] [Abstract][Full Text] [Related]
8. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
Liu X; Yue P; Zhou Z; Khuri FR; Sun SY
J Natl Cancer Inst; 2004 Dec; 96(23):1769-80. PubMed ID: 15572759
[TBL] [Abstract][Full Text] [Related]
9. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Edelman MJ; Watson D; Wang X; Morrison C; Kratzke RA; Jewell S; Hodgson L; Mauer AM; Gajra A; Masters GA; Bedor M; Vokes EE; Green MJ
J Clin Oncol; 2008 Feb; 26(6):848-55. PubMed ID: 18281656
[TBL] [Abstract][Full Text] [Related]
10. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
Liao Z; Komaki R; Milas L; Yuan C; Kies M; Chang JY; Jeter M; Guerrero T; Blumenschien G; Smith CM; Fossella F; Brown B; Cox JD
Clin Cancer Res; 2005 May; 11(9):3342-8. PubMed ID: 15867233
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study.
Ferrandina G; Ranelletti FO; Legge F; Lauriola L; Salutari V; Gessi M; Testa AC; Werner U; Navarra P; Tringali G; Battaglia A; Scambia G
Clin Cancer Res; 2003 Oct; 9(12):4324-31. PubMed ID: 14555502
[TBL] [Abstract][Full Text] [Related]
12. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
Fidler MJ; Argiris A; Patel JD; Johnson DH; Sandler A; Villaflor VM; Coon J; Buckingham L; Kaiser K; Basu S; Bonomi P
Clin Cancer Res; 2008 Apr; 14(7):2088-94. PubMed ID: 18381949
[TBL] [Abstract][Full Text] [Related]
13. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.
Groen HJ; Sietsma H; Vincent A; Hochstenbag MM; van Putten JW; van den Berg A; Dalesio O; Biesma B; Smit HJ; Termeer A; Hiltermann TJ; van den Borne BE; Schramel FM
J Clin Oncol; 2011 Nov; 29(32):4320-6. PubMed ID: 21990410
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9.
Shishodia S; Aggarwal BB
Cancer Res; 2004 Jul; 64(14):5004-12. PubMed ID: 15256475
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
Dandekar DS; Lopez M; Carey RI; Lokeshwar BL
Int J Cancer; 2005 Jun; 115(3):484-92. PubMed ID: 15688368
[TBL] [Abstract][Full Text] [Related]
16. Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study.
Chen L; He Y; Huang H; Liao H; Wei W
Med Oncol; 2008; 25(2):161-71. PubMed ID: 18172786
[TBL] [Abstract][Full Text] [Related]
17. Ubiquitous expression of cyclooxygenase-2 in meningiomas and decrease in cell growth following in vitro treatment with the inhibitor celecoxib: potential therapeutic application.
Ragel BT; Jensen RL; Gillespie DL; Prescott SM; Couldwell WT
J Neurosurg; 2005 Sep; 103(3):508-17. PubMed ID: 16235684
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
Gadgeel SM; Ruckdeschel JC; Heath EI; Heilbrun LK; Venkatramanamoorthy R; Wozniak A
J Thorac Oncol; 2007 Apr; 2(4):299-305. PubMed ID: 17409801
[TBL] [Abstract][Full Text] [Related]
19. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling.
Wang ZL; Fan ZQ; Jiang HD; Qu JM
Carcinogenesis; 2013 Mar; 34(3):638-46. PubMed ID: 23172668
[TBL] [Abstract][Full Text] [Related]
20. Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial.
Altorki NK; Christos P; Port JL; Lee PC; Mirza F; Spinelli C; Keresztes R; Beneck D; Paul S; Stiles BM; Zhang Y; Schrump DS
J Thorac Oncol; 2011 Jun; 6(6):1121-7. PubMed ID: 21532508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
